FOLFOX7治疗进展期胃癌疗效观察  

Efficacy and safety of FOLFOX7 therapy on the treatment of advanced gastric cancer

作　　者：严华[1] 杨柳[1] 郭美[1] 张哲永[1] 

机构地区：[1]上海交通大学医学院附属第九人民医院消化科,上海200011

出　　处：《世界临床药物》2013年第12期747-751,共5页World Clinical Drug

摘　　要：目的观察奥沙利铂联合氟尿嘧啶、亚叶酸钙组成的FOLFOX7方案治疗进展期胃癌的疗效和不良反应。方法 34例进展期胃癌患者接受奥沙利铂130 mg/m2静脉滴注d1,亚叶酸钙400 mg/m2静脉滴注d1,氟尿嘧啶2 400 mg/m2,静脉输液泵持续滴注46 h,21 d为1个周期,每例患者至少接受2个周期化疗方可进行疗效评价。结果 34例患者共接受141个周期化疗,中位周期数4个（2~6个）。总有效率（ORR）为44.1%（15/34）,无患者达到完全缓解（CR）,部分缓解（PR）患者占44.1%（15/34）,稳定（SD）者占47.1%（16/34）,疾病进展（PD）者占8.8%（3/34）。不良反应主要为胃肠道反应及白细胞减少,未见Ⅲ级及以上神经毒性反应发生。结论 FOLFOX7方案可作为进展期胃癌的安全化疗方案。Objective To evaluate the clinical efficacy and the toxicity of FOLFOX7 chemotherapy protocol （5-fluorouracil/leucovorin combined with oxaliplatin） for advanced gastric cancer. Methods Thirty-four patients with advanced gastric cancer were enrolled and received FOLFOX7 chemotherapy protocol. Patients who had received more than two cycles of FOLFOX7 chemotherapy were evaluated through clinical response with RECIST criteria. Results Thirty-four patients had totally received 141 cycles of chemotherapy protocol with average of 4 cycles for each patient （2-6）. The overall response rate （ORR） was 44.1% （15/34）, partial remission rate （PR） was 44.1% （15/34）, stable disease （SD） acconuted for 47.1% （16/34） and progressive disease （PD） acconuted for 8.8% （3/34）, respectively. No complete remission （CR） case was seen in our treatment. Adverse reaction of chemotherapy observed included neutropenia, nausea and vomit. There were no nerve toxicities higher than grade Ⅲ. Conclusion The FOLFOX7 chemotherapy is an effective and safer first-line treatment protocol for advanced gastric cancer.

关 键 词：奥沙利铂 氟尿嘧啶 亚叶酸钙 进展期胃癌 

分 类 号：R979.1[医药卫生—药品]